CXCR4 and diffuse large B-cell lymphoma: Reinholdt et al. demonstrated that plerixafor enhances rituximab’s effectiveness in diffuse large B-cell lymphoma (DLBCL) by reducing CXCR4 expression and increasing tumor apoptosis, supporting the potential expansion of CXCR4-targeted therapies beyond lung cancer (Reinholdt et al., 2016).